Tumor Biology

, Volume 36, Issue 9, pp 7213–7219 | Cite as

Akt2/ZEB2 may be a biomarker for exfoliant cells in ascitic fluid in advanced grades of serous ovarian carcinoma

Research Article
First Online:
Received:
Accepted:

Abstract

Ovarian cancers present a mild clinical course when diagnosed early but an aggressive pathway when diagnosed in the peri- and postmenopausal periods. However, the predictability of tumor progression is stochastic and is difficult to predict. In the present study, we hypothesized to examine the key pathways that are dysregulated to promote epithelial-mesenchymal transition in serous ovarian carcinoma. Examination of these steps would help to identify ascitic fluid with cells poised for metastasis or otherwise. We focused on examining the Akt2 expression, mainly because of its report as being overamplified in the aggressive variants of ovarian cancer, as well as TGFbeta-sensitivity of Akt2 that forms the key basis for metastasis initiation of most kinds of carcinoma. We obtained primary ovarian carcinoma samples as well as ascitic fluid and distantly metastatic ovarian carcinoma to examine the expression of Akt2. The results of the study demonstrated that in malignant exfoliated ovarian cancer cells, Smad4 expression was tremendously increased in the nuclei, suggesting nuclear translocation of Smad, which thereafter may have activated ZEB2, and thereafter genomically affected the expression of E-cadherin, myosin II, and vimentin, key components for initiating and sustaining metastasis. All of these may have been stimulated by increased cellular expression of Akt2 in metastatic variants of the serous ovarian carcinoma. The reliance on Akt2 and TGF beta signaling may also potentiate the case for Akt inhibitors or small molecule inhibitors of TGFbeta signaling like doxycycline as adjunct chemotherapy in serous ovarian carcinoma, especially the metastatic variants.

Keywords

Cancer biomarker Epithelial-mesenchymal transition Tumor spheroids Ovarian carcinoma Metastasis Ascites 
This is a preview of subscription content, log in to check access.

Notes

Conflicts of interest

None

References

  1. 1.
    Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, et al. Low grade serous ovarian carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer Treat Rev. 2015;41:136–43.CrossRefPubMedGoogle Scholar
  2. 2.
    Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, et al. Epithelial ovarian cancer: an overview. World J Transl Med. 2014;3:1–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Gadducci A, Menichetti A, Guiggi I, Notarnicola M, Cosio S. Correlation between CA125 levels after sixth cycle of chemotherapy and clinical outcome in advanced ovarian carcinoma. Anticancer Res. 2015;35:1099–104.PubMedGoogle Scholar
  4. 4.
    Janco JM, Gloviczki P, Friese JL, Cliby WA. Lymphatic mapping and ligation for persistent ascites after surgery for gynecologic malignancy. Obstet Gynecol. 2015;125:434–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Ifthikar AM, Rathod PS, Shruthi S, Pallavi VR, Shobha K, Shankaranand B, et al. Primary peritoneal carcinoma: regional cancer institute experience. Indian J Surg Oncol. 2014;5:232–6.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Chen M, Jin Y, Bi Y, Yin J, Wang Y, Pan L. A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology. Onco Targets Ther. 2014;7:1891–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Fader AN, Java J, Ueda S, Bristow RE, Armstrong DK, Bookman MA, et al. Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol. 2013;122:225–32.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hemalatha AL, Divya P, Mamatha R. Image-directed percutaneous FNAC of ovarian neoplasms. Indian J Pathol Microbiol. 2005;48:305–9.PubMedGoogle Scholar
  9. 9.
    Uguz A, Ersoz C, Bolat F, Gokdemir A, Vardar MA. Fine needle aspiration cytology of ovarian lesions. Acta Cytol. 2005;49:144–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y, et al. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther. 2006;5:779–85.CrossRefPubMedGoogle Scholar
  11. 11.
    Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih IEM, et al. Amplicon profiles in ovarian serous carcinomas. Int J Cancer. 2007;120:2613–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Clark BZ, Beriwal S, Dabbs DJ, Bhargava R. Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas. Am J Clin Pathol. 2014;142:64–71.CrossRefPubMedGoogle Scholar
  13. 13.
    Akhtar K, Sherwani R, Anees A. Synchronous ovarian carcinoma with colorectal metastases: an unusual presentation. Clin Pract. 2012;2, e53.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lan A, Qi Y, Du J. Akt2 mediates TGF-β1-induced epithelial to mesenchymal transition by deactivating GSK3β/snail signaling pathway in renal tubular epithelial cells. Cell Physiol Biochem. 2014;34:368–82.CrossRefPubMedGoogle Scholar
  15. 15.
    Lindsey S, Langhans SA. Crosstalk of oncogenic signaling pathways during epithelial-mesenchymal transition. Front Oncol. 2014;4:358.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    O'Connor JW, Gomez EW. Biomechanics of TGFβ-induced epithelial-mesenchymal transition: implications for fibrosis and cancer. Clin Transl Med. 2014;3:23.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hill L, Browne G, Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int J Cancer. 2013;132:745–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Koopmansch B, Berx G, Foidart JM, Gilles C, Winkler R. Interplay between KLF4 and ZEB2/SIP1 in the regulation of E-cadherin expression. Biochem Biophys Res Commun. 2013;431:652–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Cardenas H, Vieth E, Lee J, Segar M, Liu Y, Nephew KP, et al. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. Epigenetics. 2014;9:1461–72.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, et al. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. Hum Pathol. 2015;46:1–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Yi BR, Kim TH, Kim YS, Choi KC. Alteration of epithelial-mesenchymal transition markers in human normal ovaries and neoplastic ovarian cancers. Int J Oncol. 2015;46:272–80.PubMedGoogle Scholar
  22. 22.
    Postigo AA, Depp JL, Taylor JJ, Kroll KL. Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J. 2003;22:2453–62.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Webb PM. Environmental (nongenetic) factors in gynecological cancers: update and future perspectives. Future Oncol. 2015;11:295–307.CrossRefGoogle Scholar
  24. 24.
    Houghton SC, Reeves KW, Hankinson SE, Crawford L, Lane D, Wactawski-Wende J et al. Perineal powder use and risk of ovarian cancer. J Natl Cancer Inst. 2014;106(9).Google Scholar
  25. 25.
    Wang H, Chen H, Qin Y, Shi Z, Zhao X, Xu J et al. Risks associated with premature ovarian failure in Han Chinese women. Reprod Biomed Online. 2015.Google Scholar
  26. 26.
    Hall JM, Korach KS. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis. Mol Carcinog. 2013;52:715–25.CrossRefPubMedGoogle Scholar
  27. 27.
    Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 2012;12:91.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. Gynecol Oncol. 2014;135:118–24.CrossRefPubMedGoogle Scholar
  29. 29.
    Zhao N, Li YH, Wu XK, Wang GY, Cai DY, Han FJ. Effect of Brucea javanica fruit oil emulsion combined cisplatin on the growth inhibition of transplanted tumor in human ovarian cancer SKOV3 nude mice: an experimental study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015;35:57–62.Google Scholar
  30. 30.
    Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, et al. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. PLoS One. 2015;10(3), e0121112.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Masoumi-Moghaddam S, Amini A, Morris DL. P3.04Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer. Ann Oncol. 2015;26 Suppl 2:ii21–2.CrossRefGoogle Scholar
  32. 32.
    Desmeules P, Trudel D, Turcotte S, Sirois J, Plante M, Grégoire J et al. Prognostic significance of TIMP-2, MMP-2, and MMP-9 on high-grade serous ovarian carcinoma using digital image analysis. Hum Pathol. 2015.Google Scholar
  33. 33.
    Al-Hassan NN, Behzadian A, Caldwell R, Ivanova VS, Syed V, Motamed K, et al. Differential roles of uPAR in peritoneal ovarian carcinomatosis. Neoplasia. 2012;14:259–70.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Galazis N, Olaleye O, Haoula Z, Layfield R, Atiomo W. Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration. Fertil Steril. 2012;98:1590–601. e1.CrossRefPubMedGoogle Scholar
  35. 35.
    Wen W, Liang W, Wu J, Kowolik CM, Buettner R, Scuto A, et al. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther. 2014;13:3037–48.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Chen S, Wang J, Gou WF, Xiu YL, Zheng HC, Zong ZH, et al. The involvement of RhoA and Wnt-5a in the tumorigenesis and progression of ovarian epithelial carcinoma. Int J Mol Sci. 2013;14:24187–99.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Wu Z, Wu Z, Li J, Yang X, Wang Y, Yu Y, et al. MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumour Biol. 2012;33:1619–28.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Chao A, Lai CH, Chen HC, Lin CY, Tsai CL, Tang YH, et al. Serum microRNAs in clear cell carcinoma of the ovary. Taiwan J Obstet Gynecol. 2014;53:536–41.CrossRefPubMedGoogle Scholar
  39. 39.
    Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, et al. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014;111:1932–44.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Huang YF, Cheng WF, Wu YP, Cheng YM, Hsu KF, Chou CY. Circulating IGF system and treatment outcome in epithelial ovarian cancer. Endocr Relat Cancer. 2014;21:217–29.CrossRefPubMedGoogle Scholar
  41. 41.
    Bhutani J, Sheikh A, Niazi AK. Akt inhibitors: mechanism of action and implications for anticancer therapeutics. Infect Agent Cancer. 2013;8:49.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Tang HJ, Jin X, Wang S, Yang D, Cao Y, Chen J, et al. A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. Gynecol Oncol. 2006;100:308–17.CrossRefPubMedGoogle Scholar
  43. 43.
    Chen F, Zhuang M, Peng J, Wang X, Huang T, Li S, et al. Baicalein inhibits migration and invasion of gastric cancer cells through suppression of the TGF-β signaling pathway. Mol Med Rep. 2014;10:1999–2003.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of ObstetricsLinyi People’s HospitalLinyiChina

Personalised recommendations